NON SMALL CELL LUNG CANCER METASTATIC
Clinical trials for NON SMALL CELL LUNG CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CANCER METASTATIC trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktails tested for advanced cancers
Disease control CompletedThis early-stage study tested several combinations of cancer drugs in 60 people with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial looked at different drug mixes, including niraparib, TSR-042, bevacizumab, and various chemothera…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New combo therapy shows promise for Tough-to-Treat lung cancer spread
Disease control CompletedThis study tested a powerful three-drug combination in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain and spinal cord (meningeal metastasis). The treatment used a high dose of the targeted pill furmonertinib, plus the IV dr…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Radiation plus pills may slow spread of advanced lung cancer
Disease control CompletedThis study tested adding a precise type of radiation (SBRT) to standard targeted therapy pills for people with stage IV lung cancer that has specific gene changes (EGFR, ALK, or ROS1). The goal was to see if this combination could delay the cancer from spreading to new areas. 27 …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
Could less be more? lung cancer patients may not need endless immunotherapy
Disease control CompletedThis study looked at 265 people with advanced non-small cell lung cancer who had a protein called PD-L1. They all received a combination of two immunotherapy drugs (nivolumab and ipilimumab) for 6 months. Then, half stopped treatment and were watched closely, while the other half…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
Experimental combo targets blood vessels in lung cancer
Disease control CompletedThis early-phase study tested whether adding the experimental drug plinabulin to the standard immunotherapy nivolumab is safe and effective for people with advanced non-small cell lung cancer that has spread. Participants had already tried at least one chemotherapy. The goal was …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: Lyudmila Bazhenova, M.D. • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New hope: targeted therapy may control lung cancer spread without chemo
Disease control CompletedThis study tested whether using local ablative therapy (LAT) — treatments like radiation or surgery that target tumors directly — can control metastatic non-small cell lung cancer when a blood test shows rising cancer DNA (MRD). 37 patients with stage IV lung cancer who had stabl…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
Lung cancer combo shows promise in Late-Stage trial
Disease control CompletedThis study tested whether adding bevacizumab to the standard drug osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 01, 2026 17:57 UTC